Welcome to our dedicated page for Neuronetics news (Ticker: STIM), a resource for investors and traders seeking the latest updates and insights on Neuronetics stock.
Neuronetics, Inc. reports company developments for a commercial-stage medical technology and healthcare business centered on neurohealth therapies. Its recurring updates cover the NeuroStar Advanced Therapy System, a transcranial magnetic stimulation platform cleared by the U.S. Food and Drug Administration for adults with major depressive disorder, adjunctive use in obsessive-compulsive disorder, anxious depression symptoms in adults with MDD, and first-line adjunctive treatment of MDD in adolescent patients aged 15-21.
News about STIM also covers operating results, U.S. and international system revenue, clinic services added through the completed Greenbrook acquisition, SPRAVATO-related clinic activity, executive and board changes, inducement equity awards, shareholder engagement, and cost-structure actions.
Neuronetics (STIM) has launched the first integration of a TMS system with an EHR/EMR by connecting its TrakStar practice management platform to the AdvancedMD cloud-based EHR and revenue cycle system.
The integration lets NeuroStar TMS treatment data flow directly into AdvancedMD, where practices already manage scheduling, clinical records, and billing, aiming to reduce duplicate documentation and administrative burden across multi-session courses of care. AdvancedMD serves more than 65,000 practitioners at 13,000 independent practices, while NeuroStar has delivered over 9.1 million TMS sessions to more than 253,000 patients nationwide. The integration will be available in Q4 to NeuroStar providers currently using AdvancedMD and to those who adopt it later, and both companies plan to offer it across their customer bases following a pilot with Collaborative Solutions in Psychiatry.
Neuronetics (NASDAQ: STIM) reported second quarter 2026 revenue of $41.6 million, up 9.1% year over year, driven by Greenbrook revenue of $26.9 million, up 16.8%, while NeuroStar revenue declined 2.7% to $14.7 million. Gross margin improved to 51.1% from 46.6%.
Operating expenses fell 12% to $22.7 million, reducing loss from operations to $1.5 million from $8.1 million. Adjusted EBITDA turned slightly positive at $0.3 million versus a $5.6 million loss, and net loss narrowed to $3.4 million ($0.05 per share). Total cash was $25.0 million at June 30, 2026.
For full year 2026, Neuronetics expects revenue of $160–$164 million, gross margin of 48–50%, and operating expenses of $95–$100 million (or $91–$96 million excluding ~$4 million stock-based compensation). Projected cash flow from operations and investing is negative $10.5–$14.5 million. The company also announced senior leadership changes, including a new CFO and sales head.
Neuronetics (NASDAQ: STIM) and major shareholder Jorey Chernett, Managing Member of Pointillist Family Office, announced an “Understanding” that sets a framework for alignment among the Board, management, and Chernett, with a stated focus on maximizing long-term shareholder value.
According to Neuronetics, after engagement on the balance sheet and capital optimization, Chernett now expresses comfort with the Company’s financial position and confidence in management’s execution. Under the Understanding, Chernett may recommend a new Board member, subject to customary approvals, to enhance direct shareholder participation. The Company’s largest shareholder, Madryn Asset Management, also reaffirmed its conviction in Neuronetics’ long-term prospects and support for the Board and management.
Neuronetics (NASDAQ: STIM) granted equity inducement awards in the form of restricted stock units (RSUs) to five new non-executive employees under its 2020 Inducement Incentive Plan, as a material inducement to employment and in accordance with Nasdaq Listing Rule 5635(c)(4).
The awards cover varying RSU amounts and vest over three to four years, generally in three equal annual installments, subject to each recipient’s continued employment through the applicable vesting dates. According to Neuronetics, the grants were approved by the Compensation Committee and are subject to the plan’s terms.
Neuronetics (NASDAQ: STIM) announced the grand opening of Greenbrook Mental Wellness Centers’ National Center of Excellence in Rockville, Maryland, a nearly 7,000-square-foot flagship facility overseen by Chief Medical Officer Geoffrey Grammer, M.D. The center is designed as a national blueprint for advanced interventional psychiatry, expanding access to in-office treatments for depression and other psychiatric conditions not adequately managed by first-line therapies.
The Rockville site supports high-volume NeuroStar TMS and SPRAVATO operations, is REMS-certified, and serves as Greenbrook’s National Center for Clinical Innovation and Research. It will pilot emerging treatment modalities and, if FDA-approved, may incorporate psychedelic-class therapies into Greenbrook’s care model.
Neuronetics (NASDAQ: STIM) plans to release its second quarter 2026 financial and operating results before market open on Tuesday, August 11, 2026. On the same day, the company will host a results conference call at 8:30 a.m. Eastern Time, available via live listen-only webcast and telephone registration.
Neuronetics (NASDAQ: STIM) appointed Nir Naor as Chief Financial Officer effective July 23, 2026, bringing over 20 years of finance and life sciences experience, including CFO roles at Axogen, Arbor Pharmaceuticals and Mölnlycke’s U.S./Americas business, plus earlier senior roles at UCB and AstraZeneca.
According to Neuronetics, Naor will receive a material inducement grant of 500,000 restricted stock units vesting in four equal annual installments under the 2020 Inducement Incentive Plan, approved under NASDAQ Listing Rule 5635(c)(4). The company also confirmed Cory Anderson’s promotion to Executive Vice President and General Manager, Greenbrook effective July 1, 2026, and announced that Andrew Macan, Executive Vice President, Chief Legal Officer and Corporate Secretary, will step down effective August 15, 2026.
Neuronetics (NASDAQ: STIM) announced management will participate in B. Riley Securities' Mind, Muscle & Vision Summit, an invitation-only institutional investor event at the InterContinental Boston.
On July 16, 2026, Neuronetics will join Compass Pathways in a panel on commercializing novel neuropsychiatric drugs and hold one-on-one investor meetings. No webcast is planned.
Neuronetics (NASDAQ: STIM) appointed Robert (Rob) Greene as Senior Vice President Sales, effective June 1, 2026. Greene has extensive commercial and sales leadership experience in healthcare and medical technology.
According to Neuronetics, he received an inducement grant of 200,000 RSUs vesting in four equal annual installments under Nasdaq Listing Rule 5635(c)(4).
Neuronetics (NASDAQ: STIM) will showcase new real-world TMS data at the 2026 Clinical TMS Society (CTMSS) Annual Meeting as a Silver Sponsor. Presentations use the proprietary TrakStar database to examine NeuroStar TMS effectiveness across age, sex, adolescents, and maintenance therapy.
Neuronetics will also join the CTMSS PULSES Course to demonstrate NeuroStar navigation capabilities enabled by its partnership with ANT Neuro.